In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Circulating mitochondrial DNA predicts survival in patients with acute heart failure

Session Poster session 5

Speaker Konstantin A Krychtiuk

Event : ESC Congress 2016

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Cardiac Care – CCU, Intensive, and Critical Cardiovascular Care
  • Session type : Poster Session

Authors : KA Krychtiuk (Vienna,AT), M Lenz (Vienna,AT), G Maurer (Vienna,AT), K Huber (Vienna,AT), J Wojta (Vienna,AT), G Heinz (Vienna,AT), WS Speidl (Vienna,AT)

K.A. Krychtiuk1 , M. Lenz1 , G. Maurer1 , K. Huber2 , J. Wojta1 , G. Heinz1 , W.S. Speidl1 , 1Medical University of Vienna, Department of Internal Medicine II, Division of Cardiology - Vienna - Austria , 2Wilhelminen Hospital, 3rd Department of Internal Medicine, Cardiology and Emergency Medicine - Vienna - Austria ,

European Heart Journal ( 2016 ) 37 ( Abstract Supplement ), 983

Background: Patients suffering from acute heart failure (AHF) requiring admission to an intensive care unit (ICU) have a poor prognosis. Activation of the innate immune system contributes to the pathogenesis of AHF. Mitochondrial DNA that shows similarities to bacterial DNA may be released after tissue damage and activates the innate immune system.

Purpose: The aim of this study was to analyze whether circulating levels of mtDNA predict 30-day survival in patients with AHF.

Methods: We included 90 consecutive patients with AHF admitted to our cardiovascular ICU (33% with cardiogenic shock, 21% with acutely decompensated HF and 46% of patients suffered from AHF after cardiac arrest). Blood was taken at admission and mtDNA levels were measured by real-time PCR.

Results: Mean age was 62.1±16.0, 76.7% of patients were male and median NT-proBNP levels were 4986 (1525–23842) pg/mL. 30-day survival was 64.4%. Median mitochondrial DNA levels at admission were significantly higher in non-survivors when compared with survivors (29.6 (12.1–70.7) ng/mL vs. 20.6 (7.3–37.1 ng/mL), p<0.05). Patients with plasma levels of mtDNA in the highest quartile had a 2.6-fold higher risk of dying after adjustment for age, gender, NT-proBNP levels and APACHE II score (p<0.05).

Conclusion: Circulating levels of mtDNA predict mortality in AHF patients requiring ICU admission.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are